CEFTAZIDIME AVIBACTAM MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Ceftazidime Avibactam Market, By Type (Combination (CAZ/AVI), Ceftazidime (CAZ), and Avibactam (AVI)), By Indication (Complicated intra-abdominal infections, Complicated urinary tract infections, Hospital-acquired bacterial pneumonia, Ventilator-associated bacterial pneumonia, Bloodstream infections caused by carbapenem-resistant organisms, and Other multidrug-resistant Gram-negative infections), By Dosage Form (Injectable, Powder for Reconstitution, and Pre-filled Syringes), By Drug Type (Branded and Generic), By End User (Tertiary-care hospitals, Secondary-care hospitals, Long-term acute-care facilities, and Specialized infectious disease centers), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

Published In: 11 Dec, 2025
Code: CMI9055
Pages: 168
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

The global ceftazidime avibactam market is estimated to be valued at USD 3.43 Bn in 2025 and is expected to reach USD 5.92 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032. The global ceftazidime avibactam market represents a critical segment within the advanced antimicrobial therapeutics landscape, addressing the growing challenge of multidrug-resistant bacterial infections. Ceftazidime Avibactam, a novel combination antibiotic comprising ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor), has emerged as a breakthrough treatment option for complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia caused by gram-negative bacteria.

This innovative therapeutic combination demonstrates enhanced efficacy against carbapenem-resistant Enterobacteriaceae and other extended-spectrum beta-lactamase producing organisms, positioning it as a vital tool in combating antimicrobial resistance. The market encompasses various formulations, dosage strengths, and distribution channels across hospital pharmacies, retail pharmacies, and online platforms. With increasing prevalence of healthcare-associated infections, rising awareness about antibiotic stewardship programs, and growing investment in antimicrobial research and development, the ceftazidime avibactam market continues to expand globally. Key market participants focus on strategic collaborations, regulatory approvals, and market penetration strategies to capitalize on the substantial unmet medical need in treating resistant bacterial infections, particularly in intensive care units and immunocompromised patient populations.

Market Dynamics

The global ceftazidime avibactam market is primarily driven by the escalating prevalence of multidrug-resistant bacterial infections worldwide, particularly carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase (ESBL) producing pathogens that pose significant therapeutic challenges in clinical settings. The increasing incidence of healthcare-associated infections, rising geriatric population susceptible to complex infections, and growing awareness among healthcare professionals about antimicrobial resistance patterns fuel market demand significantly. Government initiatives promoting antimicrobial stewardship programs, substantial investments in infectious disease research, and favorable reimbursement policies for novel antimicrobial therapies further accelerate market growth. Additionally, expanding hospital infrastructure in emerging economies and increasing adoption of advanced diagnostic techniques for bacterial identification contribute to market expansion.

However, the market faces considerable restraints including high development costs associated with antimicrobial drug discovery, stringent regulatory requirements for antibiotic approvals, and potential side effects leading to limited patient compliance. The emergence of alternative treatment modalities, generic competition from existing antibiotics, and concerns regarding antibiotic resistance development with prolonged usage pose additional challenges. Price pressures from healthcare systems and limited market exclusivity periods further constrain market growth.

Nevertheless, significant opportunities exist through expanding applications in pediatric populations, development of oral formulations for outpatient treatment, strategic partnerships between pharmaceutical companies and research institutions, and penetration into untapped geographical markets. The growing focus on combination therapies, personalized medicine approaches in infectious disease management, and increasing investment in antimicrobial research present substantial growth prospects for market players seeking to address the critical global need for effective anti-infective treatments.

Key Features of the Study

This report provides in-depth analysis of the global ceftazidime avibactam market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ceftazidime avibactam market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Allergan, AbbVie, Merck & Co., Cipla, Aurobindo Pharma, Sun Pharmaceutical Industries, Lupin Pharmaceuticals, Hikma Pharmaceuticals, Sandoz, Fresenius Kabi, Dr. Reddy’s Laboratories, Zydus Lifesciences, Baxter International, and Teva Pharmaceutical Industries.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ceftazidime avibactam market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ceftazidime avibactam market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Combination (CAZ/AVI)
- Ceftazidime (CAZ)
- Avibactam (AVI)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Complicated intra-abdominal infections
- Complicated urinary tract infections
- Hospital-acquired bacterial pneumonia
- Ventilator-associated bacterial pneumonia
- Bloodstream infections caused by carbapenem-resistant organisms
- Other multidrug-resistant Gram-negative infections
Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Injectable
- Powder for Reconstitution
- Pre-filled Syringes
Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Tertiary-care hospitals
- Secondary-care hospitals
- Long-term acute-care facilities
- Specialized infectious disease centers
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
  - South Africa
  - North Africa
  - Central Africa
Key Players Insights
- Pfizer
- Allergan
- AbbVie
- Merck & Co
- Cipla
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Lupin Pharmaceuticals
- Hikma Pharmaceuticals
- Sandoz
- Fresenius Kabi
- Dr Reddy’s Laboratories
- Zydus Lifesciences
- Baxter International
- Teva Pharmaceutical Industries

Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
Market Purview
- Report Description
  - Market Definition and Scope
- Executive Summary
  - Global Ceftazidime Avibactam Market, By Type
  - Global Ceftazidime Avibactam Market, By Indication
  - Global Ceftazidime Avibactam Market, By Dosage Form
  - Global Ceftazidime Avibactam Market, By Drug Type
  - Global Ceftazidime Avibactam Market, By End User
  - Global Ceftazidime Avibactam Market, By Distribution Channel
  - Global Ceftazidime Avibactam Market, By Region
Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Industry Trends
Global Ceftazidime Avibactam Market, By Type, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Combination (CAZ/AVI)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ceftazidime (CAZ)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Avibactam (AVI)
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Ceftazidime Avibactam Market, By Indication, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Complicated intra-abdominal infections
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Complicated urinary tract infections
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospital-acquired bacterial pneumonia
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ventilator-associated bacterial pneumonia
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bloodstream infections caused by carbapenem-resistant organisms
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other multidrug-resistant Gram-negative infections
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Ceftazidime Avibactam Market, By Dosage Form, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Injectable
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Powder for Reconstitution
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pre-filled Syringes
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Ceftazidime Avibactam Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Branded
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Ceftazidime Avibactam Market, By End User, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Tertiary-care hospitals
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Secondary-care hospitals
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Long-term acute-care facilities
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialized infectious disease centers
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Ceftazidime Avibactam Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
  - Market Share Analysis, 2025 and 2032 (%)
  - Y-o-Y Growth Analysis, 2021 - 2032
  - Segment Trends
- Hospital Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
  - Introduction
  - Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Global Ceftazidime Avibactam Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
  - Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  - Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  - Regional Trends
- North America
  - Introduction
  - Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - U.S.
    - Canada
- Latin America
  - Introduction
  - Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - Brazil
    - Argentina
    - Mexico
    - Rest of Latin America
- Europe
  - Introduction
  - Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - Germany
    - U.K.
    - Spain
    - France
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - Introduction
  - Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - Introduction
  - Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - Introduction
  - Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  - Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    - South Africa
    - North Africa
    - Central Africa
Competitive Landscape
- Pfizer
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Allergan
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- AbbVie
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Merck & Co
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Cipla
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Aurobindo Pharma
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sun Pharmaceutical Industries
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Lupin Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Hikma Pharmaceuticals
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Sandoz
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Fresenius Kabi
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Dr Reddy’s Laboratories
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Zydus Lifesciences
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Baxter International
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
References and Research Methodology
- References
- Research Methodology
- About us

*Browse 32 market data tables and 28 figures on ‘Ceftazidime Avibactam Market' - Global forecast to 2032

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now